Literature DB >> 20093173

Hyperphosphorylated tau in the brains of mice and monkeys with long-term administration of ketamine.

L Y Yeung1, Maria S M Wai, Ming Fan, Y T Mak, W P Lam, Zhen Li, Gang Lu, David T Yew.   

Abstract

Ketamine, a non-competitive antagonist at the glutamatergic N-methyl-d-aspartate (NMDA) receptor, might impair memory function of the brain. Loss of memory is also a characteristic of aging and Alzheimer's disease. Hyperphosphorylation of tau is an early event in the aging process and Alzheimer's disease. Therefore, we aimed to find out whether long-term ketmaine administration is related to hyperphosphorylation of tau or not in the brains of mice and monkeys. Results showed that after 6 months' administration of ketamine, in the prefrontal and entorhinal cortical sections of mouse and monkey brains, there were significant increases of positive sites for the hyperphosphorylated tau protein as compared to the control animals receiving no ketamine administration. Furthermore, about 15% of hyperphosphorylated tau positive cells were also positively labeled by terminal dUTP nick end labeling (TUNEL) indicating there might be a relationship between hyperphosphorylation of tau and apoptosis. Therefore, the long-term ketamine toxicity might involve neurodegenerative process similar to that of aging and/or Alzheimer's disease. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20093173     DOI: 10.1016/j.toxlet.2010.01.008

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  17 in total

Review 1.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

2.  Chronic ketamine administration modulates midbrain dopamine system in mice.

Authors:  Sijie Tan; Wai Ping Lam; Maria S M Wai; Wan-Hua Amy Yu; David T Yew
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

3.  Ketamine use disorder: preclinical, clinical, and neuroimaging evidence to support proposed mechanisms of actions.

Authors:  Leah Vines; Diana Sotelo; Allison Johnson; Evan Dennis; Peter Manza; Nora D Volkow; Gene-Jack Wang
Journal:  Intell Med       Date:  2022-03-07

4.  Aging of the NMDA receptor: from a mouse's point of view.

Authors:  Kathy R Magnusson
Journal:  Future Neurol       Date:  2012-09

5.  Brain damages in ketamine addicts as revealed by magnetic resonance imaging.

Authors:  Chunmei Wang; Dong Zheng; Jie Xu; Waiping Lam; D T Yew
Journal:  Front Neuroanat       Date:  2013-07-17       Impact factor: 3.856

6.  Gene expression changes in GABA(A) receptors and cognition following chronic ketamine administration in mice.

Authors:  Sijie Tan; John A Rudd; David T Yew
Journal:  PLoS One       Date:  2011-06-21       Impact factor: 3.240

7.  Changes in hippocampal AMPA receptors and cognitive impairments in chronic ketamine addiction models: another understanding of ketamine CNS toxicity.

Authors:  Runtao Ding; Yanning Li; Ao Du; Hao Yu; Bolin He; Ruipeng Shen; Jichuan Zhou; Lu Li; Wen Cui; Guohua Zhang; Yan Lu; Xu Wu
Journal:  Sci Rep       Date:  2016-12-09       Impact factor: 4.379

8.  Chronic Ketamine Exposure Causes White Matter Microstructural Abnormalities in Adolescent Cynomolgus Monkeys.

Authors:  Qi Li; Lin Shi; Gang Lu; Hong-Luan Yu; Fu-Ki Yeung; Nai-Kei Wong; Lin Sun; Kai Liu; David Yew; Fang Pan; De-Feng Wang; Pak C Sham
Journal:  Front Neurosci       Date:  2017-05-19       Impact factor: 4.677

9.  Ketamine as antidepressant? Current state and future perspectives.

Authors:  H W W Hasselmann
Journal:  Curr Neuropharmacol       Date:  2014-01       Impact factor: 7.363

10.  Ketamine induces tau hyperphosphorylation at serine 404 in the hippocampus of neonatal rats.

Authors:  Haiyan Jin; Zhiyong Hu; Mengjie Dong; Yidong Wu; Zhirui Zhu; Lili Xu
Journal:  Neural Regen Res       Date:  2013-06-15       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.